Is Fulgent Genetics Inc (FLGT) overvalued? · rev $283.5M
Fulgent Genetics Inc (FLGT) is a diagnostics & research company listed on US.
This page asks whether Fulgent Genetics Inc (FLGT) looks expensive on cached numbers — not a short thesis.
Latest reported FLGT revenue for 2024-12-31 was $283.5M. Net income was -$43.8M. Revenue was down 2.0% from 2023-12-31 to 2024-12-31. FLGT currently screens at market cap $586.6M.
FLGT currently screens at market cap $586.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next FLGT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the FLGT stock page for the full model, not this heading.
Not investment advice.